Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Evaluate Vantage Homepage
  3. Analysis
  4. Vantage points

Vantage points

Thumbnail
June 25, 2020

Diabetes prevention signal emerges for Farxiga

SGLT2 inhibitors primarily treat diabetes, with benefits also seen in heart and kidney diseases. Might they also help prevent diabetes in the first place?

Thumbnail
March 27, 2019

Should gene therapy patients be asked to pay?

The price in value-based payment deals should by definition be justified, so why is patient cost-sharing part of the calculation? Spark covers this cost, but there is no guarantee that all gene therapy companies will.

Article image
Vantage logo
January 22, 2019

Gene therapy: how much will it cost patients?

Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…

Article image
Vantage logo
December 11, 2018

The FDA’s proposed changes to device regulation are thin on detail

The FDA has made a lot of noise about its plans to make medical devices safer. But these plans are somewhat amorphous; any meaningful steps would likely require…

Article image
Vantage logo
September 03, 2018

For drug treatment decisions machine learning must be more than a black box

The industry has its work cut out to rebuild trust in the tech following doubts about one pioneer, IBM Watson.

Article image
Vantage logo
August 11, 2018

How machines could mine forgotten data

Drug discovery is getting harder, and some companies are turning to machine learning to look for new targets.

Article image
Vantage logo
July 31, 2018

Big pharma piles into machine learning, but what will it get out of it?

Big pharma is using machine learning to improve the drug development process – but can the tech live up to the hype?

Article image
Vantage logo
July 19, 2018

The million-dollar question hanging over US research funding law

As drug prices climb, is it time to ask whether the landmark technology transfer law is a fair deal for US taxpayers?

Article image
Vantage logo
June 25, 2018

The $100,000 problem gene therapy companies would rather not mention

The high doses of recently studied gene therapies threaten manufacturing problems that few have fully considered.

Article image
Vantage logo
May 30, 2018

Reasons to be cautious about new haemophilia therapies

Roche's Hemlibra has impressed, but uptake might not be as fast as some hope.

Article image
Vantage logo
May 29, 2018

Canada’s medical cannabis ambition no laughing matter

Growing acceptance of medical marijuana could see cannabis companies coming after pharma sales.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.